Anders Pedersen - Galecto Chief Officer
| GLTO Stock | USD 5.30 0.21 3.81% |
Insider
Anders Pedersen is Chief Officer of Galecto
| Age | 64 |
| Address | Ole Maaloes Vej 3, Copenhagen, Denmark, 2200 |
| Phone | 45 70 70 52 10 |
| Web | https://galecto.com |
Galecto Management Efficiency
The company has return on total asset (ROA) of (0.3429) % which means that it has lost $0.3429 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7261) %, meaning that it created substantial loss on money invested by shareholders. Galecto's management efficiency ratios could be used to measure how well Galecto manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of December 2024, Return On Tangible Assets is likely to drop to -1.05. In addition to that, Return On Capital Employed is likely to drop to -1.29. At this time, Galecto's Non Currrent Assets Other are very stable compared to the past year. As of the 1st of December 2024, Other Current Assets is likely to grow to about 2.9 M, while Total Assets are likely to drop about 36.3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| John Castle | Monte Rosa Therapeutics | 53 | |
| Filip MD | Monte Rosa Therapeutics | 50 | |
| Jack Anders | Revolution Medicines | 48 | |
| Richard MD | Lyell Immunopharma | 72 | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Debra Canner | Amylyx Pharmaceuticals | 65 | |
| Karen Kotz | Coherus BioSciences | N/A | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
| Elizabeth Homans | Lyell Immunopharma | 58 | |
| Erick MD | Acrivon Therapeutics, Common | 66 | |
| Silvia Buonamici | Monte Rosa Therapeutics | N/A | |
| Kristina Masson | Acrivon Therapeutics, Common | 44 | |
| David Grainger | Centessa Pharmaceuticals PLC | 55 | |
| MBA CFA | Bolt Biotherapeutics | 60 | |
| Jacquelyn JD | Cullinan Oncology LLC | 46 | |
| MD MSc | Centessa Pharmaceuticals PLC | 64 | |
| Joshua MBA | Centessa Pharmaceuticals PLC | 50 | |
Management Performance
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.34 |
Galecto Leadership Team
Elected by the shareholders, the Galecto's board of directors comprises two types of representatives: Galecto inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Galecto. The board's role is to monitor Galecto's management team and ensure that shareholders' interests are well served. Galecto's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Galecto's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| Ulf Nilsson, CoFounder | ||
| BSc FRCP, CoFounder | ||
| Hakon Leffler, CoFounder | ||
| Garrett Esq, General VP | ||
| Lori Firmani, Interim Officer | ||
| Anders Pedersen, Chief Officer | ||
| MD BSc, CoFounder IPF | ||
| Pr MD, Chief Officer | ||
| Stephanie Oestreich, Chief Officer |
Galecto Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Galecto a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | (12.67 M) | ||||
| Shares Outstanding | 1.32 M | ||||
| Shares Owned By Insiders | 3.45 % | ||||
| Shares Owned By Institutions | 12.03 % | ||||
| Number Of Shares Shorted | 9.47 K | ||||
| Price To Book | 0.33 X | ||||
| EBITDA | (37.52 M) | ||||
| Net Income | (38.35 M) |
Pair Trading with Galecto
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Galecto position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Galecto will appreciate offsetting losses from the drop in the long position's value.Moving together with Galecto Stock
Moving against Galecto Stock
| 0.83 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.83 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.82 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.75 | GILD | Gilead Sciences | PairCorr |
| 0.69 | EBS | Emergent Biosolutions | PairCorr |
The ability to find closely correlated positions to Galecto could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Galecto when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Galecto - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Galecto to buy it.
The correlation of Galecto is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Galecto moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Galecto moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Galecto can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galecto. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Galecto Stock, please use our How to Invest in Galecto guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galecto. If investors know Galecto will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galecto listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.11) | Return On Assets (0.34) | Return On Equity (0.73) |
The market value of Galecto is measured differently than its book value, which is the value of Galecto that is recorded on the company's balance sheet. Investors also form their own opinion of Galecto's value that differs from its market value or its book value, called intrinsic value, which is Galecto's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galecto's market value can be influenced by many factors that don't directly affect Galecto's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galecto's value and its price as these two are different measures arrived at by different means. Investors typically determine if Galecto is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galecto's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.